e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel drugs and biomarkers in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Can blood investigations be utilised to predict treatment response to omalizumab?
C. Gouder, L. West, S. Montefort (B'Kara, Malta)
Source:
Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Session:
Novel drugs and biomarkers in respiratory medicine
Session type:
Thematic Poster Session
Number:
741
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Gouder, L. West, S. Montefort (B'Kara, Malta). Can blood investigations be utilised to predict treatment response to omalizumab?. Eur Respir J 2013; 42: Suppl. 57, 741
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
Evaluating omalizumab persistency of response after long-term therapy (XPORT)
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Added value of electronic monitoring in the assessment of asthma control?
Source: Annual Congress 2013 –Monitoring symptoms and quality of life
Year: 2013
How well can we practically apply asthma guidelines?
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
The clinical and genetic factors for predicting the response to inhaled corticosteroids
Source: International Congress 2014 – Biomarkers of asthma and clinical immunology
Year: 2014
Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
A new clinically relevant method of calculating adherence
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
The control of asthma in real life: Baseline evaluation of a long-term study
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
Safety and tolerability of acute dosing of beta-blockers in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Efficacy of omalizumab in Polish real-world patients
Source: International Congress 2016 – Asthma management
Year: 2016
E-monitoring of asthma therapy to improve compliance in children (E-MATIC)
Source: International Congress 2015 – Paediatric asthma and allergy: e-health in management
Year: 2015
REG endpoint validation: Do database asthma control measures predict future risk?
Source: International Congress 2014 – Management of asthma and other respiratory diseases in primary care
Year: 2014
Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013
What are common COPD symptoms in a real-life setting? The German DACCORD registry
Source: International Congress 2014 – COPD markers
Year: 2014
Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
In whom should regular asthma controller therapy be initiated?
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept